SRPT Lawsuit Alert! Class Action Lawsuit Against Sarepta Therapeutics

Sarepta Therapeutics (SRPT) is facing a class action lawsuit alleging the company and its senior officers made false and misleading statements regarding the safety and efficacy of its key Duchenne muscular dystrophy gene therapy, Elevidys. Shareholders claim Sarepta omitted critical information about severe side effects and potential patient deaths during the Class Period (June 22, 2023, to June 24, 2025), which was revealed by a June 24, 2025 FDA Safety Communication reporting two deaths and an investigation into acute liver failure risk associated with the drug. This legal action and the underlying safety concerns have contributed to SRPT stock losing over 85% year-to-date, signaling significant regulatory and financial headwinds for the company.

Analysis

Sarepta Therapeutics (SRPT) is facing a severe crisis centered on a class-action lawsuit and a critical U.S. FDA safety investigation concerning its flagship gene therapy, Elevidys. The lawsuit alleges that the company and its senior officers provided misleadingly positive statements about the drug's safety and efficacy between June 2023 and June 2025. During this period, management touted a "laudable safety profile" and strong commercial performance, citing cumulative sales exceeding $334 million and a 49% year-over-year increase in total net product revenue in one quarter. However, this narrative was shattered by a June 24, 2025 FDA Safety Communication which revealed an investigation into two patient deaths and the risk of acute liver failure associated with Elevidys. This disclosure gives significant credence to the lawsuit's claims of omitting critical safety information and has directly precipitated a catastrophic loss in shareholder value, with SRPT stock declining over 85% year-to-date. The situation represents a fundamental threat to the company's primary revenue driver and its credibility with regulators and investors.

Key Decisions for Investors

• Investors should closely monitor all forthcoming communications from the FDA, as any further regulatory action, such as a sales suspension or expanded black-box warning for Elevidys, presents a significant near-term downside catalyst.
• Re-evaluate all forward-looking financial models for Sarepta, as the commercial viability of Elevidys, its primary revenue source, is now in serious jeopardy, making prior revenue and earnings guidance obsolete.
• Given the 85% stock decline, the ongoing class-action lawsuit, and the unresolved FDA investigation, the risk profile for SRPT is extremely elevated; consider reducing exposure as the path to recovery is contingent on regulatory outcomes that are currently unknowable and unfavorable.